undamentalytics Newsletter
Sign in

Rapid Micro Biosystems, Inc. key statistics and ratios

In fiscal 2025, Rapid Micro Biosystems, Inc. had return on equity of -86.8% and a net margin of -140.3%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Net margin−230.6%−316.5%−354.9%−233.0%−167.2%−140.3%−145.6%
Return on equity—−156.5%−31.6%−37.2%−48.5%−86.8%—
Return on assets−53.0%−47.3%−28.2%−31.4%−38.8%−54.5%−76.8%
R&D as % of revenue40.6%42.1%75.1%56.9%52.0%40.5%38.2%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 7 checks passed · June 30, 2026
What it owns · $58m
Short-term assets $46mLonger-term assets $12m
What it owes, and who funded it · $58m
Short-term liabilities $18mLonger-term liabilities $23mShareholders' equity $18m
  • Short-term assets cover short-term liabilities $46m of assets due within a year against $18m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $46m short-term assets against $23m of longer-dated liabilities.
  • More cash than debt $15m of cash against $19m of debt.
  • Debt below 40% of shareholders' equity Debt is 108% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 0% to 108% over five years.
  • A year's operating cash flow covers at least 20% of debt −$40m of operating cash flow against $19m of debt.
  • Operating profit covers interest at least five times over Operating income of −$50m against $2m of interest.

From Rapid Micro Biosystems, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

12 /100

Weak moat

How hard Rapid Micro Biosystems's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -42.3% of total assets over 6 years.

  • Durability 10 / 20

    Operating margin has been a median -197.4%; its worst year was -334.6%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 6 years, at a median -182.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (17 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: MXCT vs RPIDOABI vs RPIDBNGO vs RPIDRPID vs TKNO

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Rapid Micro Biosystems, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Rapid Micro Biosystems, Inc.